Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

74.50USD
15 Jan 2019
Change (% chg)

$1.13 (+1.54%)
Prev Close
$73.37
Open
$73.28
Day's High
$74.89
Day's Low
$73.28
Volume
3,851,133
Avg. Vol
4,086,624
52-wk High
$80.18
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $198,512.70
Shares Outstanding(Mil.): 2,600.38
Dividend: 0.55
Yield (%): 2.88

Financials

  MRK.N Industry Sector
P/E (TTM): 34.62 29.45 30.88
EPS (TTM): 2.21 -- --
ROI: 8.65 14.34 13.80
ROE: 16.83 15.85 15.29

U.S. Supreme Court could side with Merck over Fosamax lawsuits

WASHINGTON U.S. Supreme Court justices on Monday appeared sympathetic to Merck & Co in its bid to fend off hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

07 Jan 2019

UPDATE 1-U.S. Supreme Court could side with Merck over Fosamax lawsuits

WASHINGTON, Jan 7 U.S. Supreme Court justices on Monday appeared sympathetic to Merck & Co in its bid to fend off hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

07 Jan 2019

U.S. Supreme Court could side with Merck over Fosamax lawsuits

WASHINGTON, Jan 7 U.S. Supreme Court justices on Monday appeared sympathetic to Merck & Co in its bid to fend off hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

07 Jan 2019

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

WASHINGTON The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million (£156.5 million) verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

07 Jan 2019

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

WASHINGTON The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

07 Jan 2019

UPDATE 2-Merck loses bid to revive $200 mln Gilead verdict at U.S. high court

WASHINGTON, Jan 7 The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

07 Jan 2019

Merck loses bid to revive $200 mln Gilead verdict at U.S. high court

WASHINGTON, Jan 7 The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

07 Jan 2019

Factbox: Bristol-Myers' $74 billion Celgene buy has investors looking for next deal

Bristol-Myers Squibb Co's announcement that it would buy Celgene Corp for $74 billion (59 billion pounds) has raised investors' hopes that a wave of consolidation among drugmakers could be coming. The following are some of the companies in the sector whose shares rose on Thursday on takeover speculation following the deal announcement:

03 Jan 2019

AstraZeneca's ovarian cancer drug gets FDA nod as maintenance treatment

Dec 19 The U.S. Food and Drug Administration approved AstraZeneca Plc's cancer drug developed along with Merck & Co as a first-line maintenance treatment for adults with a form of ovarian cancer, the companies said on Wednesday.

19 Dec 2018

Merck bolsters animal health unit with $2.4 billion Antelliq purchase

Merck and Co said on Friday it will buy privately held French company Antelliq Group, which makes digital identification products for livestock, for about 2.1 billion euros (1.88 billion pounds) to bolster its fast-growing animal health business.

14 Dec 2018

Earnings vs. Estimates